SRTS - Sensus Healthcare to Participate in the 36th Annual Roth Conference | Benzinga
Management will discuss its new "Fair Deal Agreement" for its SRT-100 Vision™ IG-SRT in one-on-one meetings in Dana Point, California on March 18th and 19th
BOCA RATON, Fla., March 14, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces management will participate in one-on-one or small group meetings with institutional investors at the 36th Annual Roth conference to be held March 17th – 19th in Dana Point, Calif.
During the meetings, management will discuss its new Fair Deal Agreement program, which provides an additional economic value proposition to customers and a recurring revenue model for Sensus. Management will also discuss the reception it received at its booth at the American Academy of Dermatology Annual Meeting earlier this month, as described in its recently issued press release here.
Investor participation in the conference is by invitation only. For more information or to request a meeting, please contact a Roth sales representative. To submit a registration request, visit https://ibn.fm/Roth2024Registration.
About Sensus Healthcare
Sensus Healthcare, Inc. is a global pioneer in the development and delivery of non-invasive treatments for skin cancer and keloids. Leveraging its cutting-edge superficial radiotherapy (SRT and IG-SRT) technology, the company provides healthcare providers with a highly effective, patient-centric treatment platform. With a dedication to driving ...